Quantitative lymphocyte alterations are frequent in patients with cancer, and strongly impact
prognosis and survival. The development of cancers in immunosuppressed patients has …

Abstract Disease Overview Hodgkin lymphoma (HL) is an uncommon B‐cell lymphoid
malignancy affecting 8500 new patients annually and representing approximately 10.2% of …

Background Brentuximab vedotin is an anti-CD30 antibody–drug conjugate that has been
approved for relapsed and refractory Hodgkin's lymphoma. Methods We conducted an open …

The purpose of this work was to modernize recommendations for evaluation, staging, and
response assessment of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma …

Purpose Recent advances in imaging, use of prognostic indices, and molecular profiling
techniques have the potential to improve disease characterization and outcomes in …

Background The intensive polychemotherapy regimen eBEACOPP (bleomycin, etoposide,
doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated …

Background: Population-based information about cancer occurrence and survival are
required to inform clinical practice and research; but for most lymphomas data are lacking …

Abstract Purpose: Relapsed or refractory Hodgkin lymphoma is a challenge for medical
oncologists because of poor overall survival. We aimed to assess the feasibility, safety, and …

Background Fluorine 18 (18F)− fluorodeoxyglucose (FDG) PET/CT is a routine tool for
staging patients with lymphoma and lung cancer. Purpose To evaluate configurations of …

Background Despite advances in treatments for Hodgkin's lymphoma, about 20% of patients
still die from progressive disease. Current prognostic models predict the outcome of …